ONTX News and Press, Onconova Therapeutics Inc. From 12/08/23

Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved CDK4/6 inhibitors Data support the potential use of narazaciclib in bre...

2023-11-14 20:18:07 ET Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Conference Call November 14, 2023, 04:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Steve Fruchtman - President and CEO Victor Moyo - Chief Medical Officer Mark Gue...

2023-11-14 16:07:34 ET More on Onconova Therapeutics Seeking Alpha’s Quant Rating on Onconova Therapeutics Historical earnings data for Onconova Therapeutics Financial information for Onconova Therapeutics For further details see: Onconova Therapeu...

Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational preparations for the narazaciclib program and the rigosertib trial plan expected in the...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

Onconova Therapeutics Inc. (ONTX) is expected to report $-0.26 for Q3 2023

NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced ...

Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” o...

Dr. Victor Moyo named Chief Medical Officer Meena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biop...

Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023 Additional studies support broad potential, especially in cyclin-dependent cancers NEWTOWN, Pa., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the ȁ...